Skip to main content
. 2019 Jul 9;10(43):4479–4491. doi: 10.18632/oncotarget.27065

Figure 5. Combination of CD90low CB-MSCs with VIC-008 further improved anti-tumor efficacy.

Figure 5

(A) Representative bioluminescent images of different treatment groups. (B) Quantification signal of luciferase-expressing ID8 tumor (n = 6). (C) Mice survival curve (n = 6). (D) Tumor weight at week 7 post tumor inoculation n = 5. (E) Quantification of CXCL12 in the blood serum by ELISA. n = 5.